Clinical trial · Interventional
Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors
Evaluation of Effectiveness of Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors
NCT00610844CI-TRIAL-00001159completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the effectiveness of radiofrequency ablation by pathological correlation and to characterize the tissue response after treatment of primary and secondary pulmonary tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Metastasis | Lung Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pulmonary radiofrequency ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- pulmonary radiofrequency ablation
- interventionNames
- Procedure: pulmonary radiofrequency ablation
Primary outcomes (1)
- measure
- rate of incomplete treated tumors
- timeFrame
- 3 days
Secondary outcomes (1)
- measure
- pathologic tissue changes, rate of major and minor complications
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent for radiofrequency ablation and surgery * Maximum of 3 lung tumors * Maximum tumor size 5 cm * Must be able to receive standard surgery Exclusion Criteria: * Pathological coagulation tests * Pregnant or breast feeding * Maximum tumor size more than 5 cm * Bilateral secondary lung cancer with more than 3 tumors * Inoperable patient
References
Publications (0)
Data not yet available
No reference posted for this study.